Compare · ABT vs ETON
ABT vs ETON
Side-by-side comparison of Abbott Laboratories (ABT) and Eton Pharmaceuticals Inc. (ETON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ETON operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $155.49B, about 147.4x ETON ($1.05B).
- Over the past year, ABT is down 25.2% and ETON is up 173.8% - ETON leads by 198.9 points.
- ABT has been more active in the news (12 items in the past 4 weeks vs 4 for ETON).
- ABT has more recent analyst coverage (25 ratings vs 6 for ETON).
- Company
- Abbott Laboratories
- Eton Pharmaceuticals Inc.
- Price
- $98.61+10.48%
- $37.97-1.48%
- Market cap
- $155.49B
- $1.05B
- 1M return
- +11.19%
- +18.32%
- 1Y return
- -25.16%
- +173.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 12
- 4
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Eton Pharmaceuticals Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest ETON
- President & CEO Brynjelsen Sean exercised 227,500 shares at a strike of $1.20, increasing direct ownership by 27% to 1,061,194 units (SEC Form 4)
- Chief Business Officer Krempa David converted options into 10,000 shares, increasing direct ownership by 37% to 37,025 units (SEC Form 4)
- Large owner Opaleye Management Inc. sold $4,768,637 worth of shares (126,685 units at $37.64) (SEC Form 4)
- SEC Form 4 filed by Chief Business Officer Krempa David
- Director Adams Jennifer Mckie exercised 50,000 shares at a strike of $3.78 and sold $1,623,795 worth of shares (50,000 units at $32.48) (SEC Form 4)
- Eton Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 3 filed by new insider Matthews Judith M.
- President & CEO Brynjelsen Sean sold $3,825,717 worth of shares (120,000 units at $31.88), decreasing direct ownership by 13% to 833,694 units (SEC Form 4)
- SEC Form 144 filed by Eton Pharmaceuticals Inc.
- Chief Business Officer Krempa David exercised 87,794 shares at a strike of $2.32 and sold $3,229,923 worth of shares (100,000 units at $32.30), decreasing direct ownership by 33% to 25,249 units (SEC Form 4)